Procter & Gamble Health Q1 Profit Up 45% To ₹96 Crore

Procter & Gamble Health's net profit for the first quarter of FY27 reached ₹96.15 crore, a significant 45% increase compared to ₹66.18 crore in the same quarter last year. Revenue from operations grew to ₹363.73 crore from ₹338.74 crore year-on-year.

Reader Takeaway: Strong revenue growth with profit boosted by a one-time property sale gain.

What just happened

Procter & Gamble Health Ltd announced its financial results for the quarter ending June 2026 (Q1 FY27). The company posted a net profit of ₹96.15 crore on revenue from operations of ₹363.73 crore. This profit figure includes an exceptional item of ₹31.80 crore, representing the gain from the sale of its office premises in Worli.

Why this matters

The 45% year-on-year profit growth is a significant headline figure for investors. However, the substantial contribution from the property sale means that the core operational profitability may not have grown at the same pace. Investors need to understand the recurring nature of earnings.

The backstory

The company is a part of the global Procter & Gamble group, focusing on health and wellness products in India. It operates primarily in the pharmaceutical segment and has a straightforward corporate structure with no subsidiaries, associates, or joint ventures.

What changes now

Operationally, the company continues its business in the pharmaceutical sector. The divestment of a non-core asset like an office property frees up capital and removes a fixed cost. Investors will now look towards sustained revenue and profit growth from its pharmaceutical operations in the coming quarters.

Risks to watch

While the Q1 results are positive, investors should monitor the company's ability to achieve similar profit growth without relying on exceptional items. Fluctuations in raw material costs and competition within the pharmaceutical sector remain ongoing considerations.

Peer comparison

Procter & Gamble Health operates in the broader healthcare and pharmaceutical space. While direct profit comparison is complex due to varying business models and reporting periods, companies like GlaxoSmithKline Pharmaceuticals, Abbott India, and Cipla are key players in the Indian pharmaceutical market.

Context metrics (time-bound)

For Q1 FY27 (ending June 2026), Procter & Gamble Health reported total income of ₹367.59 crore. This is a rise from ₹342.77 crore in Q1 FY26 (ending June 2025). The net profit for the quarter was ₹96.15 crore, up from ₹66.18 crore in the prior year's corresponding quarter.

What to track next

Investors should focus on the company's upcoming quarterly results to see if the operational revenue growth continues and how profit margins fare without the exceptional gain. Management commentary on future growth strategies and new product pipelines will also be crucial.